Summary:
With increasing donor age, the potential of transmitting diseases from donor to recipient reaches new dimensions. Potentially transmittable diseases from donors include infections, congenital disorders, and acquired illnesses like autoimmune diseases or malignancies of hematological or nonhematological origin. While established nonmalignant or malignant diseases might be easy to discover, early-stage hematological diseases like CML, light-chain multiple myelomas, aleukemic leukemias, occult myelodysplastic syndromes and other malignant and nonmalignant diseases might not be detectable by routine screening but only by invasive, new and/or expensive diagnostic tests. In the following article, we propose recommendations for donor work-up, taking into consideration the age of the donors. In contrast to blood transfusions, stem cells from donors with abnormal findings might still be acceptable for HCT, when no other options are available and life expectancy is limited. This issue is discussed in detail in relation to the available donor and stem cell source. Finally, the recommendations presented here aim at harmonized worldwide work-up for donors to insure high standard quality.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Thomas ED, Storb R, Clift RA et al. Bone-marrow transplantation. N Engl J Med 1975; 292: 1–19.
Gratwohl A, Baldomero H, Passweg J et al. Hematopoietic stem cell transplantation for hematological malignancies in Europe. Leukemia 2003; 17: 941–959.
Petersdorf EW, Gooley TA, Anasetti C et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 1998; 92: 3515–3520.
Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–763.
Khouri I, Keating M, Korbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies [see comments]. J Clin Oncol 1998; 16: 2817–2824.
Chakraverty R, Peggs K, Chopra R et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002; 99: 1071–1078.
Giralt S, Thall PF, Khouri I et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631–637.
McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390–3400.
Niederwieser D, Maris M, Shizuru JA et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620–1629.
Kernan NA, Bartsch G, Ash RC et al. Analysis of 462 transplantations from unrelated donors facilitated by the national marrow donor program. N Engl J Med 1993; 328: 593–602.
Hansen J, Gooley TA, Martin PJ et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998; 338: 962–968.
Hillyer CD, Josephson CD, Blajchman MA et al. Bacterial contamination of blood components: risks, strategies, and regulation. Joint ASH and AABB Educational Session in Transfusion Medicine. Hematology (Am Soc Hematol Educ Program) 2003; 1: 575–589.
Ljungman P, Lawler M, Asjo B et al. Infection of donor lymphocytes with human T lymphotrophic virus type 1 (HTLV-I) following allogeneic bone marrow transplantation for HTLV-I positive adult T-cell leukaemia. Br J Haematol 1994; 88: 403–405.
Ljungman P, Reusser P, de la Camara R et al. Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant 2004; 77: 526–531.
Ljungman P, Brand R, Einsele H et al. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 2003; 102: 4255–4260.
Kollman C, Howe RB, Anasetti C et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2003; 98: 2043–2051.
Heegaard ED, Laub Petersen B . Parvovirus B19 transmitted by bone marrow. Br J Haematol 2000; 111: 659–661.
Iwamoto M, Jernigan DB, Guasch A et al. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med 2003; 348: 2196–2203.
Sampathkumar P . West Nile virus: epidemiology, clinical presentation, diagnosis, and prevention. Mayo Clin Proc 2003; 78: 1137–1143.
Ertem M, Kurekci AE, Aysev D et al. Brucellosis transmitted by bone marrow transplantation. Bone Marrow Transplant 2000; 26: 225–226.
Martino R, Bretagne S, Einsele H et al. Reactivation of toxoplasmosis infection after allogeneic hematopoietic stem cell transplantation (HSCT). A prospective study by the European Group for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP). Blood 2003; 102: 687.
Chandrasekar PH, Momin F . Disseminated toxoplasmosis in marrow recipients: a report of three cases and a review of the literature. Bone Marrow Transplant 1997; 19: 685–689.
Mungai M, Tegtmeier G, Chamberland M, Parise M . Transfusion-transmitted malaria in the United States from 1963 through 1999. N Engl J Med 2001; 344: 1973–1978.
O'Donnell J, Goldman JM, Wagner K et al. Donor-derived Plasmodium vivax infection following volunteer unrelated bone marrow transplantation. Bone Marrow Transplant 1998; 21: 313–314.
Dharamasena F, Gordon-Smith E . Transmission of malaria by bone marrow transplantation. Transplantation 1986; 42: 228.
Salutari P, Sica S, Chiusolo P et al. Plasmodium vivax malaria after autologous bone marrow transplantation: an unusual complication. Bone Marrow Transplant 1996; 18: 473–474.
Gratwohl A, Cornu P, Speck B . Bone marrow transplantation from a donor with Gaucher's disease. Transplantation 1979; 28: 266.
Smith CI, Aarli JA, Bieberfeld P et al. Myasthenia gravis after bone-marrow transplantation. Evidence for a donor origin. N Engl J Med 1983; 309: 1565–1568.
Bellou A, Kanny G, Fremont S, Moneret-Vautrin DA . Transfer of atopy following bone marrow transplantation. Ann Allergy Asthma Immunol 1997; 78: 513–516.
Sturfelt G, Lenhoff S, Sallerfors B et al. Transplantation with allogenic bone marrow from a donor with systemic lupus erythematosus (SLE): successful outcome in the recipient and induction of an SLE flare in the donor. Ann Rheum Dis 1996; 55: 638–641.
Thomson JA, Wilson RM, Franklin IM . Transmission of thyrotoxicosis of autoimmune type by sibling allogeneic bone marrow transplant. Eur J Endocrinol 1995; 133: 564–566.
Aldouri MA, Ruggieri R, Epstein O, Prentice HG . Adoptive transfer of hyperthyroidism and autoimmune thyroiditis following allogeneic bone marrow transplantation chronic myeloid leukaemia. Br J Haematol 1990; 74: 118–119.
Kishimoto Y, Yamamoto Y, Ito T et al. Transfer of autoimmune thyroiditis and resolution of palmoplantar pustular psoriasis following allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 19: 1041–1043.
Lampeter EF, McCann SR, Kolb H . Transfer of diabetes type 1 by bone marrow transplantation. Lancet 1998; 351: 568–569.
Heyll A, Meckenstock G, Aul C et al. Possible transmission of sarcoidosis via allogeneic bone marrow transplantation. Bone Marrow Transplant 1994; 14: 161–164.
Bargetzi M, Schönberger A, Tichelli A et al. Celiac disease transmitted by allogeneic non-T cell-depleted bone marrow transplantation. Bone Marrow Transplant 1997; 20: 607–609.
Minchinton RM, Waters AH, Kendra J, Barrett AJ . Autoimmune thrombocytopenia acquired from an allogeneic bone marrow graft. Lancet 1982; 627.
Niederwieser D, Appelbaum FR, Gastl G et al. Inadvertent transmission of a donor's acute myeloid leukemia in bone marrow transplantation for chronic myelocytic leukemia. N Engl J Med 1990; 322: 1794–1796.
Baron F, Dresse M-F, Beguin Y . Transmission of chronic myeloid leukemia through peripheral-blood stem-cell transplantation. N Engl J Med 2003; 349: 913–914.
Winter TC, Keller PR, Lee FT, Pozniak MA . Donor-derived malignancy: transmission of small-cell lung cancer via renal transplantation. J Ultrasound Med 2001; 20: 559–562.
Frank S, Müller J, Bonk C et al. Transmission of glioblastoma multiforme through liver transplantation. Lancet 1998; 352: 31.
Ljungman P . Risk of cytomegalovirus transmission by blood products to immunocompromised patients and means for reduction. Br J Haematol 2004; 125: 107–116.
AuBuchon JP, Birmeyer JD, Busch MP . Safety of the blood supply in the United States: opportunities and controversies. Ann Intern Med 1997; 127: 904–909.
Dodd RY, Notari EP . Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002; 42: 975–979.
Murphy WG . Disease transmission by blood products: past, present and future. Pathophysiol Haemost Thromb 2002; 32: 1–4.
Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ . The risk of transfusion-transmitted viral infections. N Engl J Med 1996; 334: 1685–1690.
Pealer LN, Marfin AA, Petersen LR et al. Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med 2003; 349: 1236–1245.
Dodd RY . Bacterial contamination and transfusion safety: experience in the United States. Transfus Clin Biol 2003; 10: 6–9.
Abulrahi HA, Bohlega EA, Fontaine RE . Plasmodium falciparum malaria transmitted in hospital through heparin locks. Lancet 1997; 349: 23–25.
Coles AJ, Wing M, Smith S et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999; 354: 1691–1695.
Van Laar JM, Tyndall A . Intense immunosuppression and stem-cell transplantation for patients with severe rheumatic autoimmune disease: a review. Cancer Control 2003; 10: 57–65 (Review).
Trendelenburg M, Gregor M, Passweg J et al. ‘Altered immunity syndrome’, a distinct entity in long-term bone marrow transplantation survivors? Bone Marrow Transplant 2001; 28: 1175–1176.
Tyndall A, Matucci-Cerinic M . Haematopoietic stem cell transplantation for the treatment of systemic sclerosis and other autoimmune disorders. Expert Opin Biol Ther 2003; 3: 1041–1049.
McKendry RJ, Huebsch L, Leclair B . Progression of rheumatoid arthritis following bone marrow transplantation. A case report with a 13-year follow-up. Arthritis Rheum 1996; 39: 1246–1253.
Berg KD, Brinster NK, Huhn KM et al. Transmission of a T-cell lymphoma by allogeneic bone marrow transplantation. N Engl J Med 2001; 345: 1458–1463.
Kiss TJ, Chang H, Daly A et al. Bone marrow aspirates as part of routine donor assessment for allogeneic blood and marrow transplantation can reveal presence of occult hematological malignancies in otherwise asymptomatic individuals. Bone Marrow Transplant 2004; 33: 855–858.
Healey PJ, Davis CJ . Transmission of tumours by transplantation. Lancet 1998; 352: 2–3.
Kauffman HM, McBride MA, Cherikh WS et al. Transplant tumor registry: donors with central nervous system tumors. Transplantation 2002; 73: 579–582.
Schenkein DP, Schwartz RS . Neoplasms and transplantation – trading swords for plowshares. N Engl J Med 1997; 336: 949–950.
Bodo I, Peters M, Radich JP et al. Donor-derived acute promyelocytic leukemia in a liver-transplant recipient. N Engl J Med 1999; 341: 807–813.
Cleaver SA, Warren P, Kern M et al. Donor work-up and transport of bone marrow – recommendations and requirements for a standardized practice throughout the world from the Donor Registries and Quality Assurance Working Groups of the World Marrow Donor Association (WMDA). Bone Marrow Transplant 1997; 20: 621–629.
Shpilberg O, Modan M, Modan B et al. Familial aggregation of nonhematological malignancies in relatives of patients with hematological neoplasms. Br J Haematol 1994; 87: 75–80.
Grosbois B, Jego P, Attal M et al. Familial multiple myeloma: report of fifteen families. Br J Haematol 1999; 105: 768–770.
Mandla SG, Goobie S, Kumar RT et al. Genetic analysis of familial myelodysplastic syndrome: absence of linkage to chromosomes 5q31 and 7q22. Cancer Genet Cytogenet 1998; 105: 113–118.
Paltiel O, Schmit T, Adler B et al. The incidence of lymphoma in first degree relatives of patients with Hodgkin's disease and non Hodgkin's lymphoma: results and limitations of a registry linked study. Cancer 2000; 88: 2357–2366.
Acknowledgements
This work is supported in part by European Community Framework 6 European Network and the German Network Leukämie.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Niederwieser, D., Gentilini, C., Hegenbart, U. et al. Transmission of donor illness by stem cell transplantation: should screening be different in older donors?. Bone Marrow Transplant 34, 657–665 (2004). https://doi.org/10.1038/sj.bmt.1704588
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704588
Keywords
This article is cited by
-
Autoimmune cytopenias (AIC) following allogeneic haematopoietic stem cell transplant for acquired aplastic anaemia: a joint study of the Autoimmune Diseases and Severe Aplastic Anaemia Working Parties (ADWP/SAAWP) of the European Society for Blood and Marrow Transplantation (EBMT)
Bone Marrow Transplantation (2020)
-
European experience and risk factor analysis of donor cell-derived leukaemias/MDS following haematopoietic cell transplantation
Leukemia (2019)
-
A novel method as a diagnostic tool for the detection of influential observations in the Cox proportional hazards model
Quality & Quantity (2018)
-
Sixty as the new forty: considerations on older related stem cell donors
Bone Marrow Transplantation (2017)
-
The impact of improved JACIE standards on the care of related BM and PBSC donors
Bone Marrow Transplantation (2015)